[{"id":"629ff3e9-b1f6-40cc-a2f9-d6957521dc0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05394714","created_at":"2022-05-27T12:55:45.904Z","updated_at":"2024-07-02T16:35:43.167Z","phase":"Phase 1","brief_title":"A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study","source_id_and_acronym":"NCT05394714","lead_sponsor":"Medigen Biotechnology Corporation","biomarkers":" PD-L1 • CA 19-9","pipe":"","alterations":" ","tags":["PD-L1 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Magicell-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-07-12"}]